Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873975 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02873975 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 27 participants.
The verdict
NCT02873975, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This research study is studying a checkpoint kinase 1 (CHK1) inhibitor as a possible treatment for advanced solid tumors that harbor genetic alterations in the homologous repair (HR) pathway, genetic alterations that indicate replication stress, or with CCNE1 amplification.
Interventions
- DRUG LY2606368
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02873975
The ClinicalTrials.gov registry entry for NCT02873975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2606368 is the first listed.
NCT02873975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02873975 about?
NCT02873975 is a clinical study titled "A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency". This research study is studying a checkpoint kinase 1 (CHK1) inhibitor as a possible treatment for advanced solid tumors that harbor genetic alterations in the homologous repair (HR) pathway, genetic alterations that indicate replication stress, or with CCNE1 amplification.
What is the current status of trial NCT02873975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2016-10-12. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT02873975?
The interventions under investigation include: LY2606368 (DRUG).
Who is sponsoring clinical trial NCT02873975?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.